NF 1819

Discontinued Product

NF 1819 (Cat. No. 5956) has been withdrawn from sale for commercial reasons.
Description: Potent and selective irreversible MAGL inhibitor; membrane permeable and brain penetrant
Chemical Name: (3R,4S)-rel-4-(1,3-Benzodioxol-5-yl)-3-(4-fluorophenyl)-1-[1-(1H)-1,2,4-triazol-1-carbonyl)-4-piperidinyl]-2-azetidinone
Purity: ≥98% (HPLC)
Literature (4)

Biological Activity for NF 1819

NF 1819 is a potent and selective irreversible MAGL inhibitor (IC50 values are 0.25 and 7.4 nM at rMAGL and hMAGL, respectively). Exhibits 389-fold selectivity over hFAAH and exhibits minimal binding at CB receptors (IC50 > 10 μM). Alleviates symptoms in a MS in vivo model. Exhibits analgesic effects in an acute inflammatory pain model in vivo. Ameliorates neuropathic hypersensitivity induced by oxaliplatin (Cat. No. 2623). Displays high membrane permeability and brain penetrant.

Technical Data for NF 1819

M. Wt 463.46
Formula C24H22FN5O4
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1881244-28-5
PubChem ID 127032456
Smiles FC1=CC=C([C@@H]2[C@@H](C3=CC=C4OCOC4=C3)N(C2=O)C5CCN(C(N6C=NC=N6)=O)CC5)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for NF 1819

References are publications that support the biological activity of the product.

Brindisi et al (20106) Development and pharmacological characterization of selective blockers of 2-arachidonoyl glycerol degradation with efficacy in rodent models of multiple sclerosis and pain. J.Med.Chem. 59 2612 PMID: 26888301

View Related Products by Target

View Related Products by Product Action

View all Monoacylglycerol Lipase Inhibitors

Keywords: NF 1819, NF 1819 supplier, NF1819, Potent, selective, irreversible, MAGL, inhibitors, inhibits, MS, multiple, sclerosis, analgesics, neuropathic, hypersensitivity, membrane, permeable, brain, penetrant, 5956, Tocris Bioscience

Citations for NF 1819

Citations are publications that use Tocris products.

Currently there are no citations for NF 1819.

Reviews for NF 1819

There are currently no reviews for this product. Be the first to review NF 1819 and earn rewards!

Have you used NF 1819?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Cancer Metabolism Research Product Guide

Cancer Metabolism Research Product Guide

This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:

Cannabinoid Receptor Ligands Scientific Review

Cannabinoid Receptor Ligands Scientific Review

Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.